This remains an actively moving area, however: on February 27, 2026, the HHS Secretary publicly announced an intent to move roughly 14 of the 19 Category 2-listed peptides, reportedly including ipamorelin and CJC-1295, back toward Category 1 status, and multiple industry and legal-news outlets reported further FDA action in the following months easing Category 2-related restrictions on this group of peptides
We also explored the root causes of failures and explained actionable remediation strategies
Distinct from classical GH signaling (experimental): Research suggests minimal stimulation of IGF-1 and limited activation of pathways typically driven by full-length growth hormone
oral, IM, and IV have all appeared in published research
With evolving times, people are getting more inclined towards adopting a healthy lifestyle and are required to get nutritionally enriched products with more antioxidants and bioactive compounds
Macleod, J.F